During the study period, regulatory action was taken on 58 of the 60 marketing applications. Fifty-three applications were approved. A variety of clinical trial endpoints were used in the approval trials.
The basis for Food and Drug Administration (FDA) approval of a New Drug Application (NDA) and a Biologics Licensing Application (BLA) is the demonstration of efficacy with acceptable safety in adequate and well-controlled studies, and the ability to generate product labeling that defines an appropriate patient population for treatment with the drug and that provides adequate information to enable safe and effective use of the drug (1, 2) . The safety requirement was derived from the Federal Food Drug and Cosmetic Act of 1938. A 1962 amendment to that Act codified the efficacy requirement. The Act requires drug product manufacturers to establish a drug's effectiveness by "substantial evidence." Section 505(d) of the Act defines substantial evidence as "evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be concluded by such experts that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling or proposed labeling thereof" (3) . The regulation of biological products began in 1902 with the passage of the Biologics Control Act, which provided federal authority to regulate all aspects of the commercial production of vaccines, serums, toxins, and antitoxins to ensure their safety, purity, and potency. In the Public Health Services Act of 1944 (3), a biological product was specifically defined as "any virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or analogous product or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound)." The Code of Federal Regulations outlines the requirements for investigational drugs and biological products (21CFR312), licensure of BLAs (21CFR601), and drug marketing for NDAs (21CFR314) (3) . 
Background
The Office of Oncology Drug Products (OODP) in the Center for Drug Evaluation and Research at the US Food and Drug Administration began reviewing marketing applications for oncological and hematologic indications in July 2005. We conducted an overview of products that were reviewed by the OODP for marketing approval and the regulatory actions taken during July 2005 to December 2007.
Methods
We identified all applications that were reviewed by the OODP from July 1, 2005, through December 31, 2007 , and reviewed the actions that OODP took. We also sought the basis for the actions taken, including the clinical trial design, endpoints used, patient accrual in the trial(s) supporting approval, and the type of regulatory approval.
Results
During the study period, the OODP reviewed marketing applications for 60 new indications and took regulatory action on 58 indications. Regulatory action was based on a risk-benefit evaluation of the data submitted with each application. Products that demonstrated efficacy and had an acceptable risk-benefit ratio were granted either regular or accelerated marketing approval for use in the specific indication that was studied. Regular approval was based on endpoints that demonstrated that the drug provided clinical benefit as evidenced by a longer or better life or a favorable effect on an established surrogate for a longer or better life. Accelerated approval was based on a less well-established surrogate endpoint that was reasonably likely to predict a longer or better life. Of the 53 new indications that were approved during the study period, 39 received regular approval, nine received accelerated approval, and five were converted from accelerated to regular approval. Five applications were not approved, and two applications were withdrawn before any regulatory action was taken. Eighteen of the 53 indications that were approved were for new molecular entities.
Two types of FDA approval exist for drugs or biological products: regular approval and accelerated approval. Regular approval of a drug or biological product requires evidence of clinical benefit or improvement in an established surrogate endpoint for clinical benefit. As stated above, substantial evidence of efficacy from adequate and well-controlled investigations must be demonstrated (4). The FDA has interpreted this as that at least two adequate and well-controlled studies, each convincing on its own, are required to establish effectiveness (3, 5) . This interpretation reflects the need for independent substantiation of the study results that provide consistency across more than one study and reduces bias.
Independent substantiation can be obtained by using studies with identical designs or by using studies with different designs (eg, monotherapy vs combination therapy), different patient populations, different endpoints (eg, overall survival [OS] vs diseasefree survival [DFS]), or different dosage forms (eg, intravenous vs subcutaneous injection). However, the FDA has relied on only a single adequate and well-controlled efficacy study if it is a welldesigned multicenter study with demonstration of highly reliable, clinically and statistically persuasive evidence of clinical benefit (eg, OS), and when it would not be possible to conduct another study because of ethical reasons.
Accelerated approval (subpart H for NDA regulations and subpart E for BLA regulations) was promulgated in 1962 to approve drugs for patients who have serious or life-threatening diseases when these drugs provide an advantage over available therapy on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit. The applicant is then required to demonstrate that treatment with the drug is associated with clinical benefit by conducting postmarketing studies. Because a new study in an accelerated approval indication may not always be feasible, the FDA has accepted confirmatory studies in a different but related indication, usually an earlier stage of the disease.
In July 2005, the Center for Drug Evaluation and Research at FDA was reorganized, and the new Office of Oncology Drug Products (OODP) (6) was created. The OODP supervises the reviews of both NDAs and BLAs submitted to the three divisions in this office: the Division of Drug Oncology Products, the Division of Biologic Oncology Products, and the Division of Medical Imaging and Hematology Products. This review focuses on NDAs and BLAs for oncological and hematologic indications. Excluded from this review are NDAs and BLAs involving medical imaging products, applications that were submitted for dosing and safety labeling revisions, and applications for topically applied dermatological oncology products, which are reviewed by the Office of Drug Evaluation III, Division of Dermatology and Dental Products. Products that are reviewed in the Center for Biologics Evaluation and Research (eg, a vaccine to prevent cervical cancer) and the Center for Devices and Radiological Health (eg, a fluorescence in situ hybridization assay to detect overexpression of HER2/neu) are also not included in this review.
Materials and Methods
The primary sources for the data and information used in this analysis and review are the product labeling and other informa-
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Prior knowledge
In July 2005, the Office of Oncology Drug Products in the Center for Drug Evaluation and Research at the US Food and Drug Administration began reviewing marketing applications for oncological and hematologic indications.
Study design
All applications reviewed by the Office of Oncology Drug Products from July 1, 2005 through December 31, 2007, were identified, and the actions taken were reviewed.
Contribution
Marketing applications for 60 new indications were reviewed during the study period. On 58 of the indications, regulatory action was taken based on a risk-benefit evaluation. A total of 53 new indications were approved: 39 received regular approval, nine received accelerated approval, and five were converted from accelerated to regular approval. Two applications were withdrawn before action was taken, and five were not approved.
Implications
Regulatory action was taken on most of the marketing applications submitted during the study period, and 53 of the 60 applications were approved.
Limitations
Approvals were based on various study designs and primary outcomes or endpoints. Some approvals were from single-arm nonrandomized controlled trials in cases when the FDA deemed it impractical to conduct randomized studies.
From the Editors
tion that is publicly available under the Freedom of Information Act. This review covers new oncology drug and biological licensing applications and supplemental applications that were approved for new uses by the OODP between July 1, 2005, and December 31, 2007 (7-31) . A new Act, the Food and Drug Administration Amendments Act, was enacted by congress on September 27, 2007 . The majority of the applications for marketing approval of drug products reviewed in 2008 and thereafter had to conform to this new Act, and hence December 31, 2007, was chosen as the cutoff date for this review. In this review, the term "oncology drugs" includes both drug products and biological oncology products and therapeutic proteins that were reviewed in the OODP. When an NDA or BLA is submitted to the OODP, the application is assigned to receive a priority review (6-month review cycle) or a standard review (10-month review cycle). A priority review designation is assigned when preliminary review of the application indicates that the drug product, if approved, may provide one of the following in the treatment, prevention, or diagnosis of a disease: 1) evidence of increased effectiveness in treatment, prevention, or diagnosis of disease; 2) elimination or substantial reduction of a treatmentlimiting drug reaction; 3) documented enhancement of patient compliance; or 4) evidence of safety and effectiveness in a new subpopulation. All nonpriority applications are designated as standard review applications.
The five most commonly used outcomes or endpoints to evaluate a new oncological drug product are OS, DFS, time to progression (TTP), progression-free survival (PFS), and objective response rate (ORR). The FDA's recommendations regarding acceptable endpoints for the evaluation of oncology drug products are described in the Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics (32) . In this review, we used the endpoint definitions that were used in the applications that were submitted to the FDA and which can be found in approved labeling. The endpoint of OS, which is evaluated in randomized studies, is defined as the time from random assignment to the date of death due to any cause or to the date of censoring at the last time at which the subject was known to be alive in the intent-to-treat population. DFS, which is used when there is no sign of remaining disease at study initiation, is defined as the time from random assignment to cancer recurrence or death from any cause, whichever occurs first. TTP is defined as the time from random assignment to disease progression, and PFS is defined as the time from random assignment to disease progression or death from any cause, whichever occurs first. ORR is defined as the proportion of subjects with a predefined amount of reduction in tumor burden, as assessed on the basis of specific criteria such as the RECIST (Response Evaluation Criteria in Solid Tumors) criteria (33) . In general, when using ORR for evaluating efficacy, the duration of response (time from response to disease progression) is considering the regulatory decision. We retrieved the following information from the product labels, publicly available information and published reports, on the drug product, the indication, the study designs, the endpoints, and the regulatory action taken. Tables 1-6 . These tables include the drug product, the indicated use of the product, the study design(s) that provided the data for product evaluation, the endpoints that were considered in the regulatory action, the regulatory action taken (accelerated or regular approval), whether a priority or standard review of the application was conducted, and whether the product was a new molecular entity (ie, whether it was being approved for marketing for the first time for any indication in the United States). (Table 1) . Forty-four of the approved indications were based on data and results from a single study (Table 1) . Of the products approved for the 53 indications, 18 were new molecular entities and 35 were existing products that were approved for supplemental indications (Table 2 ). These approval actions included 39 priority reviews and 14 standard reviews ( Table 3 ). The FDA did not approve five indications-all for new molecular entities-after the completion of the review cycle.
Of the 53 marketing approvals, 39 received regular approval based on demonstration of clinical benefit, nine received accelerated approval, and five were converted from accelerated to regular approval (Table 4) . Anastrozole was initially granted accelerated approval for the treatment of early-stage breast cancer based on a study with limited follow-up and was converted to regular approval based on data from extended follow-up that established its longterm effects. The decisions to convert the remaining four products from accelerated to regular approval were based on data from new studies. Although lenalidomide was granted approval under subpart H regulations for both myelodysplastic syndrome and multiple myeloma, because of the requirement of restricted distribution to reduce and mitigate potential fetal harm, no further confirmatory study was deemed necessary to establish its efficacy; hence, in this review, we classified these indications as regular approvals for lenalidomide from an efficacy evaluation viewpoint.
The OODP considered a variety of endpoints or outcomes in its evaluation of the efficacy of a product (Table 6 ). Among the 44 indications that received regular approval, 10 used an OS endpoint (sample sizes ranging from 141 to 878 patients), four used DFS, three used PFS and OS, 11 used PFS or TTP, 10 used ORR (including complete response, objective response rate, major cytological response, and major hematologic response), and six used other novel endpoints (Table 5 ). These novel endpoints included reduction in hepatic iron, asparagine depletion, red blood cell transfusion independence, hemoglobin stabilization, occurrence of venous thromboembolism, and reduction in tissue injury from chemotherapy extravasation. Of the nine indications that were granted accelerated approval, one was based on TTP, six were based on ORR, and one was based on other novel endpoints (Table 5) .
Thirty-seven of the 53 indications were based on data from randomized studies. These randomized studies included 17 "add-on" studies in which the investigational drug plus standard chemotherapy was compared with the standard chemotherapy alone, four studies in which placebo was the comparator, and four studies in which best supportive care was the comparator ( Table 1 ). The study sample sizes in the randomized studies ranged from 87 patients for the use of eculizumab in paroxysmal nocturnal hemoglobinuria to 19 747 patients for the use of raloxifene for the reduction in risk of invasive breast cancer. The remaining 16 indications were based on data from single-arm studies with no comparison group. In these studies, the sample sizes ranged from 18 patients for the use of imatinib mesylate in dermatofibrosarcoma protuberans to 232 patients for the use of nilotinib hydrochloride monohydrate in chronic-phase chronic myeloid leukemia (Table 1) . Forty-four of the 53 indications were based on results from a single study.
During the study period, only five products were not approved. Information provided herein on these nonapproved products is in the public domain (34) (35) (36) (37) (38) (39) (40) . The five oncology drug products that were not approved include 1) atrasentan for hormone-refractory prostate cancer patients (34), 2) oblimersen sodium injection in combination with fludarabine and cyclophosphamide for relapsed or refractory chronic lymphocytic leukemia (35), 3) oral beclomethasone dipropionate for graft-vs-host disease (36), 4) motexafin gadolinium for brain metastasis from non-small cell lung cancer (37), and 5) mifamurtide for the adjuvant treatment of osteosarcoma (38) . Atrasentan, oral beclomethasone dipropionate, motexafin gadolinium, and mifamurtide did not demonstrate benefit with respect to the primary endpoint of efficacy in the study that was intended to support approval. During the study period, two applications were withdrawn before an FDA regulatory action was * 5-FU = 5-fluorouracil; ALL = acute lymphocytic leukemia; AP = accelerated phase; ASM = aggressive systemic mastocytosis; BSC = best supportive care; CEL = chronic eosinophilic leukemia; CLL = chronic lymphocytic leukemia; CML = chronic myelogenous leukemia; CORE = continuing outcomes relevant to evista; CP = chronic phase; CRC = colorectal cancer; CTCL = cutaneous T-cell lymphoma; CVP = cyclophosphamide; DFSP = dermatofibrosarcoma protuberans; DVT = deep vein thrombosis; EGFR = epidermal growth factor receptor; ESA = erythropoieses-stimulating agents; FAB = French-American-British; FISH = fluorescence in situ hybridization; GIST = gastrointestinal stromal tumors; HCC = hepatocellular carcinoma; HES = hypereosinophilic syndrome; IFN-a = interferon alpha; IPSS = International Prognostic Scoring System; LB = lymphoid blasts; MB = myeloid blasts; MDS = myelodysplastic syndrome; MM = multiple myeloma; MORE = multiple outcomes of raloxifen evaluation; MPD = myeloproliferative disease; NHL = non-Hodgkin lymphoma; NSCLC = non-small cell lung cancer; PDGFR = platelet-derived growth factor receptor; PE = pulmonary embolism; Ph+ = Philadelphia chromosome positive; PNH = paroxysmal nocturnal hemoglobinuria; RA = refractory anemia; RBC = red blood cell; RCC = renal cell carcinoma; RT = radiation therapy; RUTH = raloxifen use for the heart; SCCHN = squamous cell carcinoma of head and neck; SCLC = small cell lung cancer; STAR = study of tamoxifen and raloxifen; VTE = venous thromboembolism. 
Discussion
The OODP, FDA, took regulatory action on 58 of the 60 marketing applications between July 1, 2005, and December 31, 2007. A total of 53 applications were approved, two applications were withdrawn before any regulatory action was taken, and five applications were not approved. Of the 53 indications that were approved during this period, 39 received regular approval, nine received accelerated approval, and five were converted from accelerated to regular approval. FDA regulatory actions are based on an evaluation of the riskbenefit profile of the product that uses data from clinical trials Table 1 for exact labeled indication. ALL = acute lymphocytic leukemia; AP = accelerated phase; ASM = aggressive systemic mastocytosis; CEL = chronic eosinophilic leukemia; CLL = chronic lymphocytic leukemia; CML = chronic myelogenous leukemia; CP = chronic phase; CRC = colorectal cancer; CTCL = cutaneous T-cell lymphoma; DFSP = dermatofibrosarcoma protuberans; GIST = gastrointestinal stromal tumors; HCC = hepatocellular carcinoma; HES = hypereosinophilic syndrome; LB = lymphoid blasts; MB = myeloid blasts; MDS = myelodysplastic syndrome; MM = multiple myeloma; MPD = myeloproliferative disease; NHL = non-Hodgkin lymphoma; NSCLC = non-small cell lung cancer; Ph+ = Philadelphia chromosome positive; PNH = paroxysmal nocturnal hemoglobinuria; RCC = renal cell carcinoma; SCCHN = squamous cell carcinoma of head and neck; SCLC = small cell lung cancer; VTE = venous thromboembolism. provided by the applicant to support the marketing approval of a drug product. The supporting trials must allow a valid comparison to a control group and must provide a quantitative assessment of the drug's effect. The marketing approval is based both on the quantity and on the quality of the data. Although FDA regulations require data from more than one independent study to establish the efficacy of a new product, in oncology, few marketing product applications are submitted based on more than one study. During the period covered in this review, 44 approved indications were based on data and results from a single study (Table 1) . When evaluating results from a single study, internal consistency across centers in a multicenter study and among different endpoints (eg, OS, PFS, and ORR) and subgroups (eg, sex, performance status, age, and prior therapy) within a study are important. Oncology product marketing applications often contain data from only one phase III randomized clinical study; however, data from phase I and phase II clinical studies may also be used to provide supporting data. For a supplemental indication in which the safety profile of the product is known and the product's efficacy has been established in at least one previous indication, a demonstration of efficacy based on data from a single study is generally acceptable. Data from two studies are generally recommended when considering approval based on a noninferiority claim because of the uncertainty in the true treatment effect (41, 42) .
In considering approval or nonapproval of an application of a product, the magnitude of the product's effect on an endpoint and the safety profile of the drug are evaluated in a risk-benefit analysis. The magnitude of the treatment effect should be statistically persuasive and clinically meaningful. Although no specific P value has been used in evaluating results from a single study, the results from single studies should be highly statistically significant and the drug being evaluated should have a clinically meaningful superior treatment effect based on the primary endpoint of the study and corroborative treatment effect must be observed in secondary endpoints. The product safety profile must be acceptable in view of the magnitude of the efficacy and the condition being treated. In evaluating the risk-benefit analysis for consideration of regulatory approval by FDA, the following issues are considered: 1) toxicity (eg, severity of toxicity, whether Table 1 for exact labeled indication. ALL = acute lymphocytic leukemia; AP = accelerated phase; ASM = aggressive systemic mastocytosis; CEL = chronic eosinophilic leukemia; CLL = chronic lymphocytic leukemia; CML = chronic myelogenous leukemia; CP = chronic phase; CRC = colorectal cancer; CTCL = cutaneous T-cell lymphoma; DFSP = dermatofibrosarcoma protuberans; GIST = gastrointestinal stromal tumors; HCC = hepatocellular carcinoma; HES = hypereosinophilic syndrome; LB = lymphoid blasts; MB = myeloid blasts; MDS = myelodysplastic syndrome; MM = multiple myeloma; MPD = myeloproliferative disease; NHL = non-Hodgkin lymphoma; NSCLC = non-small cell lung cancer; Ph+ = Philadelphia chromosome positive; PNH = paroxysmal nocturnal hemoglobinuria; RCC = renal cell carcinoma; SCCHN = squamous cell carcinoma of head and neck; SCLC = small cell lung cancer; VTE = venous thromboembolism. it is irreversible, number of patients affected, and duration of toxicity); 2) existing available therapy; 3) refractoriness of the disease (eg, whether patients have therapeutic options); and 4) regulatory context (a new molecular entity vs a supplemental indication). Because this risk-benefit analysis is subjective, in cases where the benefit is marginal, advice from the Oncologic Drug Advisory Committee of the FDA, including communitybased clinical experts is sought before a decision on the marketing approvability of drug under review is made. The marketing applications submitted during the study period were based on data from a variety of clinical trial designs. Sixteen of the 53 approvals were based on single-arm studies (Table 1) . ORR generally is the only endpoint that can be reliably assessed in a single-arm trial because the observed effect on tumor size reduction is directly attributed to the drug and is generally not associated with the natural history of the disease.
Single-arm studies have limitations. Single-arm studies can only evaluate monotherapy and cannot isolate the effect of the new drug when it is used in combination because there is no comparative treatment arm as in a randomized study. It is not useful to compare results of single-arm studies with those of historical studies of monotherapy because such comparisons are nonrandomized, can only attempt to control for known prognostic factors, and are not be able to control for unknown prognostic factors. In addition, single-arm studies do not allow an evaluation of time-to-event endpoints (ie, OS, DFS, TTP, and PFS) because they lack information on when the event would have occurred in a group that did not receive the product being tested. Single-arm studies also cannot evaluate patient-reported subjective outcomes (eg, health-related quality of life and symptom evaluation) because they lack a comparator arm and a blinded evaluation. Evaluation of a drug's safety is also difficult when only data from single-arm trials are submitted. In this case, distinguishing adverse effects of the drug from adverse effects of the disease is difficult or impossible without a control arm that compares the investigational drug with a placebo or another treatment.
The FDA has recognized that it may be impractical to conduct randomized studies in diseases for which there is no available therapy and the disease population is small. The 53 new approved indications reported in this review included treatment of diseases (Table continues) * See Table 1 for exact labeled indication. ALL = acute lymphocytic leukemia; AP = accelerated phase; ASM = aggressive systemic mastocytosis; CEL = chronic eosinophilic leukemia; CLL = chronic lymphocytic leukemia; CML = chronic myelogenous leukemia; CP = chronic phase; CRC = colorectal cancer; CTCL = cutaneous T-cell lymphoma; DFSP = dermatofibrosarcoma protuberans; GIST = gastrointestinal stromal tumors; HCC = hepatocellular carcinoma; HES = hypereosinophilic syndrome; LB = lymphoid blasts; MB = myeloid blasts; MDS = myelodysplastic syndrome; MM = multiple myeloma; MPD = myeloproliferative disease; NHL = non-Hodgkin lymphoma; NSCLC = non-small cell lung cancer; Ph+ = Philadelphia chromosome positive; PNH = paroxysmal nocturnal hemoglobinuria; RCC = renal cell carcinoma; SCCHN = squamous cell carcinoma of head and neck; SCLC = small cell lung cancer; VTE = venous thromboembolism. † Approved under subpart H because of restricted distribution access, no further confirmatory study required for demonstration of clinical benefit. ‡ Regular approval granted based on long-term follow-up establishing safety and efficacy, which resulted in change of indication statement in the label. that affect small patient populations, such as dermatofibrosarcoma protuberans. Dermatofibrosarcoma protuberans accounts for less than 0.1% of malignant neoplasms and approximately 1% of all soft tissue sarcomas and has an estimated incidence of 0.8-5 cases per million population per year (43) . Other examples in which approvals were based on single-arm trials because randomized trials were impractical included aggressive systemic mastocytosis, hypereosinophilic syndrome and chronic eosinophilic leukemia, relapse or refractory pediatric Philadelphia chromosome-positive acute lymphocytic leukemia, cutaneous T-cell lymphoma, and mantle cell lymphoma. Response rate was the primary endpoint in these single-arm trials. Different primary outcome measures or endpoints were used to evaluate the indications discussed in this report. In a study intended for marketing registration of a product, primary endpoints should be selected prospectively and depend on the patient population, available therapies, the expected magnitude of treatment effect, and a risk-benefit analysis. OS is an endpoint that is a direct measure of clinical benefit. Symptom improvement and other patient-reported outcomes are also direct measures of clinical benefit and should be evaluated in well-conducted placebo-controlled randomized studies. The FDA's current thinking on patientreported outcomes is outlined in the "FDA draft Guidance to Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims" (44) (45) (46) .
OS is considered the gold standard for demonstrating clinical benefit and is an important endpoint in evaluating a drug's safety. Ten of the 53 approvals during the study period were based on OS. OS is an unambiguous outcome measure because it is evaluated on a continuous time scale, which gives precise accuracy for the time of the event. However, large studies may be necessary to show modest improvements in OS and longer follow-up is necessary for OS than for other endpoints, such as PFS. The sample sizes of the 10 indications approved based on superior OS ranged from 141 patients with small cell lung cancer (oral topotecan) to 878 patients with nonsquamous non-small cell lung cancer (bevacizumab) ( Table 1) .
Unlike OS, the endpoints of DFS, PFS, and TTP are not measured continuously, and thus, the exact day of recurrence or progression cannot be captured in studies that use these outcomes. The documented TTP depends on the frequency and completeness Table 1 of tumor assessments and the selection of target lesions used in the evaluation. Assessment of progression is complex and includes composite results from radiological examinations, laboratory tests, and physical examinations. Marginal differences in PFS or TTP that are observed between study arms may be because of differences in subjective assessments of progression and may not represent clinically meaningful improvement (47) (48) (49) . In addition, the results of the analysis may be influenced by any imbalance in assessment dates or missing data between treatment arms. Consideration of PFS or TTP as the primary endpoint for demonstration of efficacy for drug product approvals by FDA is based on the magnitude of the effect and the risk-benefit profile of the drug product. In the analysis of TTP, deaths without documented progression are censored, which may lead to biased estimates; by contrast, PFS includes death and captures treatment effects that are not mediated through tumor burden. PFS is preferred to TTP as a regulatory endpoint (50). In this review, nine indications were approved based on PFS and three indications were approved based on TTP (Table 5 ). In its approval of drugs, the FDA considers durable ORRs of clinically meaningful magnitude, including rates of complete and partial responses. Durable complete remission rates have led to regular approval of drugs used in the treatment of acute leukemia. In acute leukemia, durable high complete remission rates are associated with longer survival, a lower incidence of infection, and a reduction in the need for transfusions (1) . During the study period, 10 of the 16 indications that were approved based on response rates were granted regular approvals. For example, bortezomib for use in mantle cell lymphoma, dasatinib and imatinib mesylate for use in Philadelphia chromosome-positive acute lymphocytic leukemia, and vorinostat for use in cutaneous T-cell lymphoma were granted regular approval based on a durable response rate.
ORR as a surrogate endpoint that is reasonably likely to predict clinical benefit was used in granting accelerated approval. Although the FDA's accelerated approval regulations allow drug approvals based on well-conducted studies that use surrogate endpoints that are reasonably likely to predict clinical benefit, the applicant is During the study period, different study designs were used to evaluate the approved indications. The efficacy of a drug can be evaluated by either a superiority trial or a noninferiority trial. Randomized controlled superiority trials directly demonstrate an improvement in clinical benefit over an existing therapy or placebo and/or best supportive care and are generally easy to interpret. Of the 37 randomized studies that were included as supportive of the indication under review, 34 were superiority trials that demonstrated superior efficacy over placebo or best supportive care, or over standard therapy.
Noninferiority analyses are usually conducted when a drug is believed to be less toxic and to have comparable efficacy (or less efficacious by a prespecified acceptable amount) compared with an existing or standard therapy. During the study period, raloxifene hydrochloride for the use in the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and at high risk for invasive breast cancer was evaluated for a noninferiority claim. A study with a noninferiority hypothesis can only be considered to demonstrate efficacy if the existing comparative therapy (active control) has established efficacy, the active control effect size can be estimated in the indication, and the percentage of the active control effect size to be retained can be prespecified (41, 42, 51) . The optimal way to establish the treatment effect size of the active control is through a meta-analysis of historical, randomized, placebo-controlled studies. Estimation of effect size based on a single study does not include study-to-study variation, and it introduces uncertainty regarding the estimate of the active control effect. This uncertainty must be reconciled by making judgments and assumptions and by using conservative estimates of the effect size.
In evaluating trials that have a noninferiority hypothesis, an assumption that must be carefully assessed is the constancy of the treatment effect over time that is attributed to the active comparator. Because medical practice, clinical trial conduct, the timing of tumor progression assessments, the radiological modalities used, and criteria and definition for assessing progression may have evolved over time and may vary between studies, OS rather than PFS or TTP should be the primary endpoint in noninferiority trials (41) . The percentage of the active control effect to be retained should be prespecified. During this study period, in the approval of raloxifene hydrochloride, the STAR study comparing raloxifene hydrochloride to tamoxifen established noninferior efficacy (raloxifene hydrochloride potentially losing up to 35% of the tamoxifen effect [estimated incidence rate of 3.21 per 1000 personyears] on reduction of invasive breast cancer) (52).
Clinical studies with adaptive sequential designs have provided another way to evaluate new drug products. These types of studies provide decision rules for terminating the trial if a predefined magnitude of efficacy or futility is demonstrated. This flexibility ensures that patients are not treated with an ineffective drug or are offered effective drugs if early substantial clinical benefit is observed. Superior efficacy at interim analyses was observed for the following drugs: sunitinib malate in gastrointestinal stromal tumors, lapatinib in ErbB2-overexpressing metastatic breast cancer, sorafenib in hepatocellular carcinoma, and lenalidomide and liposomal doxorubicin hydrochloride in multiple myeloma. Table 7 presents the results of the interim analyses that led to the approval of these indications.
Drugs that target a specific molecular marker have the advantage of allowing the selection of a patient population that may preferentially benefit with either enhanced efficacy or reduced toxicity compared with the general population. These targeted drugs have been extensively evaluated and usually require the development of an in vitro diagnostic assay (53) . During the study period, the following targeted therapies received approval: lenalidomide for the use in patients with myelodysplastic syndrome associated deletion 5q cytogenetic abnormality, rituximab in CD20-positive diffuse large B-cell non-Hodgkin lymphoma, panitumumab and cetuximab in epidermal growth factor Table 1 for exact labeled indication. GIST = gastrointestinal stromal tumors; HCC = hepatocellular carcinoma; MM = multiple myeloma; OS = overall survival; TTP = time to progression.
receptor-expressing metastatic colorectal cancer, trastuzumab in HER2-overexpressing adjuvant breast cancer, and lapatinib in HER2-overexpressing metastatic breast cancer. Five marketing applications were not approved during the study period. The content of the regulatory action letters is not publicly available under the Freedom of Information Act; Trade Secrets Act; or the Federal Food, Drug, and Cosmetic Act, which limits our discussion of these drugs. The information provided in this review is in public domain (34) (35) (36) (37) (38) (54) (55) (56) (57) . Four applications were discussed by the Oncologic Drugs Advisory Committee. Four of the five applications did not meet the primary endpoint of the study.
We undertook this review to provide an overview of recent regulatory actions by the FDA OODP. A recent report indicates that only a small percentage of oncology drugs are successful in their development and will ultimately receive marketing approval (58) . The reasons for the attrition include a lack of reliable preclinical models (59), the failure to identify an effective dose, and the failure to characterize the oncological diseases and molecular targets. However, the majority of drugs [estimates range from 95% (60) to 74% (61) ] are discontinued before regulatory submission. Of the 60 indications that were reviewed during the study period, only five were not approved and two applications were withdrawn before a regulatory decision was reached. Among the indications that were not approved, all submitted single trials for regulatory consideration and four did not meet the prespecified primary endpoint. This review discusses marketing approvals of NDA, BLA, or supplemental applications that were based on the successful completion of well-conducted trials whose endpoints and designs were prospectively agreed on with FDA. The FDA has used recent regulatory mechanisms, including priority review status and accelerated approval, to expedite these reviews. 
